The anticoagulant treatment dilemma in pulmonary embolism associated to cancer

1 Dalen JE. Pulmonary embolism: what have we learned since Virchow? Natural history, pathophysiology, and diagnosis. Chest 2002; 122:1440-56. Search in Google Scholar

2 Keron C. Natural history of venous thromboembolism. Circulation 2003;107:122-30. Search in Google Scholar

3 Konstantinides SV, Torbicki A, Agnelli G et al. 2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism. The Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). Endorsed by the European Respiratory Society ( ERS). Eur Heart J 2014; 35, 3033-3080. Search in Google Scholar

4 Goldhaber SZ. Pulmonary Embolism. In: Bonow RO, Mann DL, Zipes DP, et al. Braunwaldʼs Heart Disease: A Textbook of Cardiovascular Medicine, Philadelphia, 9^th Ed. 2012;1679-1695. Search in Google Scholar

5 Timp JF, Braekkan SK, Versteeg HH, Cannegieter SC. Epidemiology of cance-associated venous thrombosis. Blood 2013; 122(10):1712-1723. Search in Google Scholar

6 Ginghină C. Mic Tratat de Cardiologie, Ediția a II-a; Editura Academiei Române, București 2017. Search in Google Scholar

7 Khorana AA, Kuderer NM, Culakova E, et al. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 2008; 111(10): 4902-4907. Search in Google Scholar

8 Eduard A. Cardiologie Clinică, Editura: Medicala Callistro 2015; p 721-737. Search in Google Scholar

9 Zamrano JL, Lancellotti P, Munoz DR et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. Eur Heart J 2016; 37, 2768-2801. Search in Google Scholar

10 Louzada ML, Carrier M, Lazo-Langner A, et al. Development of a clinical prediction rule for risk stratification of recurrent venous thromboembolism in patients with cancer-associated venous thromboembolism. Circulation 2012, 126(4):448-454. Search in Google Scholar

11 Petriș A., Țînț D., Tatu-Chițoiu G., Petrescu L., Tromboembolismul pulmonar în situații speciale. Editura pim Iași 2017; p 197-207. Search in Google Scholar

12 Akl EA, Vasireddi SR, Gunukula S, et al. Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer. Cochrane Database Syst Rev 2011, (6): CD006649. Search in Google Scholar

13 Carrier M, Le Gal G, Cho R, et al. Dose escalation of low molecular weight heparin to manage recurrent venous thromboembolic events despite systemic anticoagulation in cancer patients. J Thromb Haemost 2009, 7(5):760-765. Search in Google Scholar

14 Kearon C, Akl EA, OrnelasJ, et al. antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. Chest 2016;149(2):315-352 Search in Google Scholar

15 Mantha S, Ansell J. Indirect comparison of dabigatran, rivaroxaban, apixaban and edoxaban for the treatmentof acute venous thromboembolism. J Thromb Thrombolysis 2015;39(2):155-156. Search in Google Scholar

16 Carrier M, Cameron C, Delluc A, Castellucci L, Khorana AA, Lee AY. Efficacy and safety of anticoagulant therapy for the treatment of acute cancer-associated thrombosis: a systematic review and meta-analysis. Thromb Res. 2014;134(6):1214-1219. Search in Google Scholar

17 Bochenek T, Nizankowski R. The treatment of venous thromboembolism with low-molecular-weight heparins. A meta-analysis. Thromb Haemost. 2012;107(4):699-716. Search in Google Scholar

18 Castellucci L.A, Cameron C, Le Gal G, et al. Clinical and safety outcomes associated with treatment of acute venous thromboembolism: a systematic review and meta-analysis. JAMA.2014;312(11):1122-1135. Search in Google Scholar

19 van Es N, Coppens M, Schulman S, Middeldorp S, Buller HR.Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. Blood. 2014;124(12):1968-1975. Search in Google Scholar

20 Chai-Adisaksopha C, Crowther M, Isayama T, Lim W. The impact of bleeding complications in patients receiving target-specific oral anticoagulants: a systematic review and meta-analysis. Blood.2014;124(15):2450-2458. Search in Google Scholar

21 Bloom BJ, Filion KB, Atallah R, Eisenberg MJ. Meta-analysis of randomized controlled trials on the risk of bleeding with dabigatran. Am I Cardiol. 2014;113(6):1066-1074. Search in Google Scholar

22 Touma L, Filion KB, Atallah R, Eberg M, Eisenberg MJ. A meta-analysis of randomized controlled trials of the risk of bleeding with apixaban versus vitamin K antagonists. Am J Cardiol. 2015;115(4):533-541. Search in Google Scholar

23 Boutitie F, Pinede L, Schulman S, et al. Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants’ data from seven trials. BMJ. 2011;342:3036 Search in Google Scholar

24 Prandoni P, Noventa F, Ghirarduzzi A, et al. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients. Haematologica. 2007;92(2):199-205. Search in Google Scholar

25 Prandoni P, Lensing AWA, Cogo A, et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med.1996;125(1):1-7. Search in Google Scholar

26 Palareti G, Legnani C, Lee A, et al. A comparison of the safety and efficacy of oral anticoagulation for the treatment of venous thromboembolic disease in patients with or without malignancy. Thromb Haemost. 2000;84(5):805-810. Search in Google Scholar

27 Carrier M, Righini M, Le Gal G. Symptomatic subsegmental pulmonary embolism: what is the next step? J Thromb Haemost.2012;10(8):1486-1490 Search in Google Scholar

28 Stein PD, Goodman LR, Hull RD, Dalen JE, Matta F. Diagnosis and management of isolated subsegmental pulmonary embolism: review and assessment of the options. Clin Appl Thromb Hemost. 2012;18(1):20-26. Search in Google Scholar

29 Le Gal G, Righini M, Parent F, van Strijen M, Couturaud F. Diagnosis and management of subsegmental pulmonary embolism.J Thromb Haemost. 2006;4(4):724-731. Search in Google Scholar

30 den Exter PL, van Es J, Klok FA, et al. Risk profile and clinical outcome of symptomatic subsegmental acute pulmonary embolism. Blood. 2013;122(7):1144-1149; quiz 1329. Search in Google Scholar

31 Farge D, Debourdeau P, Beckers M, et al. International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. J Thromb Haemost.2013:11(1):56-70. Search in Google Scholar